Jazz Pharmaceuticals plc

NASDAQ:JAZZ  
109.46
+2.03 (+1.89%)
5:10:04 PM EDT: $105.05 -4.41 (-4.03%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)6.95B
Current PE16.76
Forward PE 5.78
2yr Forward PE 5.21
See more stats
Estimates Current Quarter
Revenue$956.83 Million
Adjusted EPS$4.20
See more estimates
10-Day MA$109.67
50-Day MA$118.38
200-Day MA$125.51
See more pivots

Jazz Pharmaceuticals plc Stock, NASDAQ:JAZZ

Waterloo Exchange, Waterloo Road, Dublin, Dublin 4
Ireland
Phone: +353.1.634.7800
Number of Employees: 2800
http://www.jazzpharmaceuticals.com

Description

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.